Ekso Bionics to Report Third Quarter 2021 Financial Results on November 2, 2021

RICHMOND, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the third quarter 2021 after the close of trading on Tuesday, November 2, 2021. Management will host a conference call beginning at 1:30 p.m. PT, 4:30 p.m. ET to discuss the financial results and recent business developments.

A live webcast of the event will be available in the "Investors" section of the Company's website at <u>www.eksobionics.com</u>, or by <u>clicking here</u>. Investors interested in listening to the conference call may do so by dialing 877-407-3036 for domestic callers or 201-378-4919 for international callers.

A replay of the call will be available for two weeks by dialing 877-660-6853 for domestic callers or 201-612-7415 for international callers and using Conference ID: 13723545. The webcast will also be available on the Company's website for one month following the completion of the call.

About Ekso Bionics[®]

Ekso Bionics[®] is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance, and mobility across medical and industrial applications. Founded in 2005, the Company continues to build upon its industry-leading expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe. Ekso Bionics is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol "EKSO." For more information, visit: <u>www.eksobionics.com</u> or follow @EksoBionics on Twitter.

Investor Contact: David Carey 212-867-1768 investors@eksobionics.com



Source: Ekso Bionics Holdings, Inc.